Status:
COMPLETED
SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)
Lead Sponsor:
Bayer
Conditions:
Chronic Bronchitis
Eligibility:
All Genders
18+ years
Brief Summary
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other ant...
Detailed Description
The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.
Eligibility Criteria
Inclusion
- Acute exacerbation of chronic bronchitis from Anthonisen type I or II
- FEV1 of \< 50 %
- Patient must be ensured in the statutory health insurance
- Further contraindications of the prescribed pharmaceutical products must be considered
Exclusion
- Patients who change from one cohort to the other
Key Trial Info
Start Date :
December 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
345 Patients enrolled
Trial Details
Trial ID
NCT00879008
Start Date
December 1 2009
End Date
August 1 2010
Last Update
June 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Germany